
	Where results make sense

Topic: Murigen

Related Topics

Verbeia

Aericura

Tamesis

Tethra

Cethlion

Elen

Morrigan

Gae Bulg

Birog

Celtic mythology

Neal Dow

Ceridwen

Sabrina

Lia Fail

List of Celtic mythological beings

In the News (Tue 24 Nov 09)

Northern Trust

Marvin Harrison

Peter Chernin

Gary Locke

Match Play

Penelope Cruz

Mickey Rourke

AR Rahman

Danny Boyle

Hugh Jackman

	Hierarch Morgana Murigen
		Morgana Murigen was the Pan-Celtic warrior magickian goddess Morgana and the Irish, Scottish and Manx enchantress lake goddess Murigen.
		Because of Morrigan Murigen's unceasingly relentless and often caustically strident efforts to further her own personal agendas, she was often seen in the guise of a storm crow hovering above the bodies of dead and dying warriors on Celtic battlefields.
		When Murigen was a young queen, the Breton hero god Gugemar journeyed on an enchanted boat to her land, and, she tended a wound he had received while hunting.
	www.blessingscornucopia.com /Hierarchs_of_Twelve_Universal_Rays_Hierarch_Morgana_Murigen_Morgaine_Morgan_Morrigan_Morrigu_Muireartach.htm (1275 words)

	Scottish Maes Howe and Morgana (Site not responding. Last check: 2007-10-04)
		Morgana Murigen (Morgaine, Morgan, Morrigan, Morrigu, Muireartach) was a Pan-Celtic triple mother goddess known by many names like "Controller of Destinies and Fates", "Enchantress Queen of the Fairies", "Great Queen Goddess", "Queen and Ruler of the Mystical Island of Avalon", and "Supreme War Goddess".
		Morgana Murigen is a Shamanic Shapeshifter, reknown for her ancient wisdom, knowledge of healing plants, and prophetic visions.
		Morgana Murigen shares her Sacred Site focal point with her soulmate husband Gugemar, as well as, a group of Restoration Omniangels, the Scotland Maes Howe Restoration Omniangels.
	www.blessingscornucopia.com /Myths_Legends_Folklore_Epics_Tales_Storytelling_Scottish_Maes_Howe_and_Morgana.htm (1246 words)

	PharmaLive: MuriGen Therapeutics Announces Investment by Starfish Ventures
		MuriGen’s flagship program is the development of a new class of drugs that target arthritis and other inflammatory diseases.
		MuriGen’s drug discovery platform is central to a number of collaborative initiatives focused on the discovery of novel drug targets for thrombocytopenia and other blood conditions, epilepsy, thalassemia and certain inflammatory conditions.
		MuriGen Therapeutics is building a portfolio of novel drugs for unmet medical needs across a number of therapeutic areas including arthritis, thrombocytopenia, inflammation, epilepsy and thalassemia.
	www.pharmalive.com /News/index.cfm?articleid=401377&categoryid=36,61 (621 words)

	WEHI News - Press Release - 2oth of February 2006
		Under the agreement Zenyth and MuriGen will jointly fund research and development of the potential drug on a cost sharing basis through to completion of proof-of-concept in human clinical trials.
		Zenyth Therapeutics Limited is an Australian biotechnology company focused on the development and commercialisation of antibody-based therapies in the areas of inflammation and cancer.
		MuriGen Therapeutics is an Australian-based drug discovery and development company established by the Walter and Eliza Hall Institute of Medical Research and four of Australia's leading scientists.
	www.wehi.edu.au /news/press/20february2006.html (759 words)

	MURIGEN THERAPEUTICS (Site not responding. Last check: 2007-10-04)
		MuriGen Therapeutics is an Australian based drug discovery and development company
		MuriGen is building a portfolio of novel drugs for unmet medical needs across a number of therapeutic areas including arthritis, thrombocytopenia, inflammation, epilepsy and thalassemia.
		By leveraging its proprietary drug discovery platform, MuriGen Therapeutics is working towards the validation of novel drug targets that have the potential to provide significant benefits for researchers, health care practitioners, and patients.
	www.murigen.com.au (80 words)

	Australian Biotechnology News \| Zenyth, MuriGen collaborate on inflammation targets
		Zenyth Therapeutics (ASX:ZTL), formerly Amrad, and unlisted Walter and Eliza Hall Institute (WEHI) spinout MuriGen Therapeutics are to co-develop a new class of drugs that target arthritis and other inflammatory diseases.
		The collaboration aims to develop therapeutic antibodies based on recent findings by scientists at WEHI that blocking the activity of G-CSF (cytokine granulocyte colony stimulating factor) can have a profound impact on the development of inflammatory diseases in animal models.
		"MuriGen are mainly focused on target discovery," said Nash.
	www.biotechnews.com.au /index.php?id=1933114179&fp=8&fpid=4 (373 words)

	[No title] (Site not responding. Last check: 2007-10-04)
		The first is between Walter and Eliza Hall Institute of Medical Research (WEHI) and MuriGen Pty Ltd, the second between MuriGen Pty Ltd and Zenyth Therapeutics.
		According to Adams, "Zenyth and MuriGen will jointly fund research and development of the potential drug on a cost sharing basis, through to completion of proof-of-concept in human clinical trials", following which the best course for commercialisation of the drug will be ascertained.
		She said the drug would be especially important given social factors such as "the ageing population and the need for treatments of arthritis and other inflammatory diseases".
	www.piper-alderman.com.au /piperald.nsf/IPTBody/19?OpenDocument (995 words)

	Nextec Biosciences (Site not responding. Last check: 2007-10-04)
		Currently, he is engaged in a number of activities involving strategic advice and capital raising in the field of Biotechnology.
		They include; iBIO Pty Ltd his consultancy company and MuriGen Pty Ltd. He is a Director of Melbourne Ventures Pty Ltd, the University of Melbourne’s Commercialisation Company and a member of the Council of the Australian Institute of Marine Science.
		He is a past member of the Australian Research Council serving on a number of sub committees.
	www.nextecbiosciences.com.au /wwwroot/board/board.html (402 words)

	Zenyth Therapeutics - G-CSF antagonists (Site not responding. Last check: 2007-10-04)
		Zenyth and MuriGen Therapeutics are co-developing antagonists of G-CSF, including therapeutic antibodies that inhibit the activity of G-CSF or its receptor, for the treatment of rheumatoid arthritis (RA) and other inflammatory diseases.
		Zenyth and MuriGen will jointly fund research and development of the potential drug on a cost sharing basis through to completion of proof-of-concept in human clinical trials.
		Zenyth’s scientists are using Dyax’s phage display library in an effort to identify fully-human antibodies suitable for development.
	www.zenyth.com.au /page.asp?departmentID=519 (420 words)

	ABOUT US (Site not responding. Last check: 2007-10-04)
		Dr Samaras is a Fellow of the Australian Institute of Management and the Australian Institute of Company Directors and a Williamson Fellow, Leadership Victoria.
		Dr Samaras consults to and is a member of several organizations including: Chairman of Replikun Biomed Pty Ltd., CEO of MuriGen Therapeutics, Non Executive Director of Rockeby biomed Ltd (ASX:RBY), Non Executive Director of Teeleostin Pty Ltd, Non Executive Director of the Australian Genome Research Facility and Non Executive Director of the Australian Phenomics Facility.
		He is a member of the NHMRC Research Committee, Visiting Fellow of the John Curtain School of Medical Research, Australian National University, Honorary Associate of the Faculty of Medicine, Nursing and Health Sciences, Monash University and Honorary Scientific Associate, School of Molecular Sciences, Faculty of Science, Technology and Engineering, La Trobe University.
	www.australisbio.com.au /pages/about.html (253 words)

	Biospace.com (Site not responding. Last check: 2007-10-04)
		Melbourne, Australia: December 20, 2006: MuriGen Therapeutics, a drug discovery and development company originally spun-out from the Walter and Eliza Hall Institute of Medical Research, today announced the successful completion of a AUD$5 million investment by leading Australian venture capital firm, Starfish Ventures.
		Zenyth Therapeutics (ZTL.AX) And MuriGen Therapeutics To Collaborate On New Drug
		Melbourne, Australia - February 20, 2006 - Zenyth Therapeutics Ltd and MuriGen Therapeutics, today announce a collaboration agreement to co-develop a new class of drugs that target arthritis and other inflamatory diseases.
	www.biospace.com /news_company.aspx?companyID=1001326 (86 words)

	Servants of Fortuna Forums - View Profile: Murigen Carylle
		Servants of Fortuna Forums - View Profile: Murigen Carylle
		Send a message via email to Murigen Carylle
		Murigen Carylle is not a member of any public groups
	sof-guild.com /forum/member.php?u=691 (37 words)

Try your search on: Qwika (all wikis)